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Abstract: Retinoids exert antitumor effects through the retinoic acid receptor α (RARα). In the
present study, we sought to identify the factors involved in the RARα-mediated transcriptional
regulation of the tumor suppressor gene and the tissue factor pathway inhibitor 2 (TFPI2) in
hepatocellular carcinoma (HCC). All-trans-retinoic acid (ATRA) was used in the in vitro experiments.
Cell invasiveness was measured using trans-well invasion assay. ATRA significantly increased
TFPI2 expression through RARα in a human HCC cell line known as HuH7. TFPI2 was vital in
the ATRA-mediated suppression of HuH7 cell invasion. The musculo-aponeurotic fibrosarcoma
oncogene homolog B (MAFB) significantly enhanced the activation of the TFPI2 promoter via RARα
while MAFF inhibited it. The knockdown of RARα or MAFB counteracted the ATRA-mediated
suppression of HuH7 cell invasion while the knockdown of MAFF inhibited the invasion. TFPI2
expression in HCC tissues was significantly downregulated possibly due to the decreased expression
of RARβ and MAFB. Patients with HCC expressing low MAFB and high MAFF levels showed the
shortest disease-free survival time. These results suggest that MAFB and MAFF play critical roles in
the antitumor effects of retinoids by regulating the expression of retinoid target genes such as TFPI2
and can be promising for developing therapies to combat HCC invasion.
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1. Introduction
Preclinical studies have shown that retinoids possess anticancer effects against different cancer
cell lines in vitro [1–3]. Moreover, it was also demonstrated that retinoids reduced cancer risk by 70%
in animal models [4,5]. The retinoic acid receptor α (RARα) is a central mediator of pleiotropic actions
of retinoids. Many other factors also take part in retinoid action by modulating the transactivating
functions of RARα. For example, a nuclear receptor co-repressor and a short heterodimer partner bind
to RARα and suppress its function [6,7] while SP1 and the B-cell translocation gene 1 activate RARα
via direct interaction [8,9]. Since retinoids produce severe side effects including tetracarcinogenesis,
mucocutaneous cytotoxicity, and hypertriglyceridemia [10], elucidating the mechanism underlying
retinoid-facilitated transcriptional regulation is crucial in developing next-generation retinoid-acting
drugs with an improved specificity.
The tissue factor pathway inhibitor 2 (TFPI2) is a serine protease inhibitor that targets the factor
VIIa–tissue factor complex as well as trypsin and plasmin [11,12]. TFPI2 indirectly inhibits the
activation of the matrix metalloprotease (MMP), which needs trypsin and plasmin and suppresses
cancer invasion [13–16]. This antitumor effect is supported by the fact that TFPI2 is silenced in various
tumors including hepatocellular carcinoma (HCC) [15,16]. Therefore, agents with the ability to restore
TFPI2 expression in tumors could be promising for developing novel antitumor drugs. Moreover,
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clarifying the mechanism underlying TFPI2 transcriptional regulation may be helpful in furthering
our understanding of tumor development and progression.
In the present study, we aimed to investigate the effect of retinoids on TFPI2 expression and
its regulatory mechanism. In addition, we asked whether TFPI2 is involved in retinoid-induced
suppression of cancer cell invasion. Finally, it was addressed whether TFPI2 and factors involved in
TFPI2 expression affect the prognosis of patients with HCC.
2. Results
2.1. TFPI2 Is Transcriptionally Regulated by ATRA
Both HuH7 and HepG2 cell lines are derived from highly differentiated human HCC and are
functionally similar in many aspects [17]. The mRNA levels of RARβ, which is a typical retinoid target
gene, increased owing to ATRA in both the cell lines in a time-dependent and dose-dependent manner
(see Figure 1A,B). However, ATRA increased TFPI2 mRNA levels only in HuH7 cells and not in HepG2
cells (see Figure 1A,C). Note that the TFPI2 gene expresses three transcript variants. The primers for
TFPI2 were designed to detect all three variants.
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(red) and RARβ (blue) mRNA in HuH7 (left) and HepG2 (right) cells following incubation with 
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Figure 1. ATRA-induced TFPI2 expression i cells. (A) Dose-dependent expression of TFPI2
(red) and RARβ (blue) mRNA in HuH7 (left) and HepG2 (right) cells following incubation with ATRA
for 12 h (n = 4). * p < 0.05 (vs. 0 µM ATRA; Dunnett’s test), (B,C) Time courses of RARβ (B) and TFPI2
(C) mRNA expression in HuH7 (left) and HepG2 (right) cells following incubation with EtOH (blue)
and 2 µM ATRA (red) for the indicated periods of time (n = 4).
The RNA polymerase inhibitor actinomycin D (ActD) was added to the cells with ATRA to
investigate whether ATRA increased the stability of TFPI2 mRNA. TFPI2 mRNA was more stable than
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RARβ mRNA in both of the HCC cell lines (see Figure 2A,B). However, the increase in TFPI2 mRNA
levels due to ATRA in HuH7 cells was abolished by ActD (see Figure 2A), which suggests that ATRA
transcriptionally regulates TFPI2 expression.
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Figure 2. Transcriptional regul i of TFPI2 expression by TRA in HuH7 cells. (A,B) HuH7 (A)
and epG2 (B) cells pre-treated with ActD incubated with EtOH (blue) and 2 µM ATRA (red) for
the indicated times. Left, RARβ, right, TFPI2 (n = 4); (C) HuH7 and HepG2 cells pre-treated with
N-hydroxy-N′-phenyloctanediamide (SAHA) (blue) and AzC (red) incubated with EtOH and 2 µM
ATRA for 12 h. RARβ (Left), TFPI2 (right) (n = 4). * p < 0.05 (vs. non-treatment control), # p < 0.05
(EtOH vs. 2 µM ATRA in the presence of SAHA or AzC) (Tukey–Kramer’s test).
5-Aza-2′-d oxycytidine (AzC) and N-hydroxy-N′-phenyloctanediamide (SAHA) are inhibitors
of DNA methyltransferase a d histone de cetylase, respectively. These reagents significantly
upregulated RARβ expression in both HuH7 and HepG2 cells, which was further boosted by ATRA
(see Figure 2C). AzC instead of SAHA induced TFPI2 expression in HepG2, which suggested that
epigenetic suppression by DNA methylation was released in the cells. Despite that, ATRA failed to
influence TFPI2 expression (see Figure 2C). These results suggest that ATRA-induced TFPI2 expression
is independent of the epigenetic mechanisms.
2.2. Through TFPI2, ATRA Suppresses HuH7 Cell Invasion
To investigate the biological significance of ATRA-induced TFPI2 expression, TFPI2 was stably
knocked down in HuH7 cells using expression vectors of short hairpin RNA (shRNA) targeting
TFPI2 (shTFPI2-1 and shTFPI2-2). We also created a control clone transfected with non-targeting
shRNA (shNT). These cells were referred to as T2KD-1, T2KD-2, and NT cells, respectively. Although
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ATRA-induced TFPI2 expression was observed in T2KD-1 and T2KD-2 cells, it was decreased by
approximately 50% and 15%, respectively, when compared with that in NT cells (see Figure 3A).
The expression of the TFPI2 protein in T2KD-2 cells was also decreased when compared with NT cells
and it is upregulated by ATRA, which was observed in NT cells. This was completely abolished in
T2KD-2 cells (see Figure 3B). Treatment with ATRA for 48 h significantly suppressed the invasion of
NT cells in a dose-dependent manner while this suppression with respect to T2KD-1 and T2KD-2 cells
was significantly impaired, which correlated with the knockdown efficiency (see Figure 3C). Although
TFPI2 is responsible for the ATRA-mediated inhibition of HuH7 cell invasion, ATRA also suppressed
HepG2 cell invasion without inducing TFPI2 (see Figures 1A and S1), which suggested that ATRA
employs several mechanisms to suppress cancer invasion in the context of cell lines.
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Figure 3. Abrogation of the suppressive effect of ATRA on HuH7 cell invasion by TFPI2 knockdown.
(A) TFPI2 mRNA expression in HuH7 cells stably transfected with shNT, shTFPI2-1, and shTFPI2-2
(NT, T2KD-1, and T2KD-2 cells, respectively). The cells were treated with EtOH (blue) and 2 µM ATRA
(red) for 12 h (n = 4). * p < 0.05 (EtOH vs. 2 µM ATRA), # p < 0.05 (vs. shNT) (Tukey–Kramer’s test);
(B) TFPI2 expression in NT nd T2KD 2 cells. The cells w re treated with EtOH (E) and 2 µM ATRA
(A) for 48 h. Glyceraldehyde-3-ph sphate dehydrogenase (GAPDH) was hown as the loading control
(C) Invasion capability of NT, T2KD-1, and T2KD-2 cells. The cells were treated with µM (blue), 1 µM
(light red), 2 µM (red), and 4 µM (dark red) of ATRA for 48 h (n = 6). * p < 0.05 (EtOH vs. 2 µM ATRA),
# p < 0.05 (vs. shNT) (Tukey–Kramer’s test).
We then performed the microarray analysis to assess the expression profiles of NT and T2KD-2
cells in the presence or absence of 2 µM ATRA for 12 and 36 h. In total, 2061 probes and 961 probes
with 1.5-fold or more changes in shTFPI2-2 at 12 and 36 h, respectively, were clustered into two groups
(Cluster A, shNT > shTFPI2-2 at 12 h, Cl ster B, shNT < shTFPI2-2 at 12 h, Cluster C, shNT > shTFPI2-2,
36 h, Cluster D, s NT < shTFPI2-2, 36 h) (see Figure S2). This cluster analysis also showed that changes
in gene expression induced by ATRA were not markedly different for shNT and shTFPI2-2, which
indicated that TFPI2 is a downstream factor of the retinoid signaling. Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway analysis of the clustered genes showed that TFPI2 may be involved in
the pathways related to cellular motility (hsa04151, hsa04360, and hsa04510), coagulation (hsa04610),
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nutritional metabolism (hsa00430, hsa01230, hsa01100, hsa00010, hsa00051, hsa01230, and hsa03320),
and xenometabolism (hsa00980, hsa00860, hsa00983, hsa05034, and hsa05204) (see Figure S2).
2.3. MAFB and MAFF Modulate the Transactivation Activity of RARα on Human TFPI2 Promoter
Genome-wide binding analysis of musculoaponeurotic fibrosarcoma (MAF) F and MAFK in
HepG2 cells from the ENCODE project [18] showed their binding sites in the region around the
transcriptional start site of the human TFPI2 (see Figure S3A). This region was inserted upstream of
the luciferase gene for reporter assays. RARα, RXRα, MAF, MAFA, MAFB, and MAFG significantly
increased the promoter activity while MAFF and MAFK showed no effect (see Figure 4A). Only RARα
showed enhanced transactivation activity in response to ATRA (see Figure 4A). Co-transfection
with RXRα, MAF, MAFA, and MAFB enhanced the transactivation activity of RARα while MAFF
was suppressed (see Figure 4B). Only MAFB maintained the responsiveness of RARα to ATRA
while the remaining transcription factors abrogated it (see Figure 4B). Therefore, we chose to focus
on investigating the effects of MAFB and MAFF on TFPI2 promoter activity. MAFB enhanced
the transactivation activity of RXRα only in the presence of ATRA while MAFF showed no effect
(see Figure S4A). The effects of MAFB and MAFF on the RXRα/RARα heterodimer were similar to
those on RARα (see Figure S4A). Co-transfecting MAFB and MAFF showed that the transactivation
activity of MAFB remained unaffected by MAFF (see Figure S4B).
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In general, RARα binds to a tandem repeat of the consensus sequence 5′-RGKTCA-3′, which is
termed the half-site [19]. However, the repeat sequence was not found in the promoter sequence of
human TFPI2. Instead, four half-sites were present (see Figure S3A). In addition, two MAF-binding
sites have been predicted by the ORCA toolkit [20]. Therefore, mutations were introduced into each
of the four half-sites (mutR1–4) and two putative MAF-biding sites (mutM1–2) (see Figure S3A).
The effects of RARα and MAFB/MAFF on the TFPI2 promoter were, respectively, eliminated by mutR4
and mutM1 even in the presence of ATRA (see Figures 4C,D and S4C,D). These results helped us
identify the MAF recognition element (MARE) and retinoic acid response element (RARE) at +6 and
+66 relative to the transcription start site, respectively (see Figure S3B). Furthermore, these MARE
and RARE were highly conserved among mammalian genomes (see Figure S3B). Binding of RARα
with MAFB or MAFF was not observed under our experimental conditions (see Figure S5). Therefore,
MAFB and MAFF might indirectly interact with RARα on the TFPI2 promoter.
2.4. MAFB, MAFF, and RARα Regulate TFPI2 Expression in HuH7 Cells and Their Invasion
HuH7 cells with stably knocked down RARα and MAFB (RaKD and MBKD cells, respectively)
showed a decreased expression of TFPI2 while those with knocked down MAFF (MFKD) showed an
increased TFPI2 expression (see Figures 5A and S6A). Furthermore, HuH7 cells stably overexpressing
MAFB (MBOE) showed a marked increase in TFPI2 expression while those overexpressing MAFF
(MFOE) showed a decrease (see Figure S6B). ATRA-mediated suppression of cell invasion was
significantly impaired by shRARα and shMAFB while MFKD cells showed a marked reduction
in cell invasion irrespective of ATRA (see Figure 5B).
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expression in HuH7 cells stably transfected with shNT, shRARα, shMAFB, or shMAFF (NT, RaKD,
MBKD, and MFKD cells, respectively). The cells were treated with EtOH (blue) or 2 µM ATRA (red) for
12 h (n = 4). * p < 0.05 (EtOH vs. 2 µM ATRA), # p < 0.05 (vs. shNT) (Tukey–Kramer’s test); (B) Invasion
capability of HuH7 cells stably transfected with shNT, shRARα, shMAFB, or shMAFF. The cells were
treated with 0 µM (blue), 1 µM (light red), 2 µM (red), and 4 µM (dark red) of ATRA for 48 h (n = 8).
* p < 0.05 (vs. 0 µM ATRA), # p < 0.05 (vs. shNT) (Tukey–Kramer’s test).
2.5. RARα and MAFB Contribute to the Downregulation of TFPI2 in HCC
We checked whether the factors involved in TFPI2 transcription plays a role in human HCC.
We performed quantitative PCR with 44 cDNA samples derived from eight normal, five fatty, three
hepatitis, five cirrhotic, and 23 HCC liver tissues (see Table S1). The expression of TFPI2, RARβ,
MAFB, and MAFF was significantly lower in HCC than that in normal liver tissue (see Figure 6).
MAFB expression was also downregulated in fatty and cirrhotic liver tissues. The role of epigenetic
mechanisms aside, the downregulation of TFPI2 can be attributable to the decreased expression of
RARβ and MAFB in HCC. Correlation analysis demonstrated that the mRNA expression of TFPI2
in the clinical samples was significantly correlated with those of MAFB and MAFF (see Figure S7).
Taking into account the observation that MAFF did not affect MAFB-induced activation of the TFPI2
promoter (see Figure S4B), MAFB may play a more important role in hepatic TFPI2 expression than
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the other transcription factors. Furthermore, MAFB and RARα expression in HCC was significantly
downregulated as the TNM stage and histological grade increased while no correlation between TFPI2
and tumor grades was observed (see Table S2).Int. J. Mol. Sci. 2018, 19, x 7 of 16 
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Figure 6. Gene expression in different types of liver diseases. Box and whisker plots of relative gene
expression levels of TFPI2, RARα, RARβ, MAFB, and MAFF to β-actin in normal (N, n = 8; blue),
fatty (FL, n = 5; green), hepatitis (Hs, n = 3; yellow), cirrhotic (Cir, n = 5; orange), and hepatocellular
carcinoma (Tu, n = 23; red) liver tissues. Boxes indicate first and third quartiles and median values and
whiskers represent 5 and 95 percentiles. Open circulars indicate outliers. * p < 0.05 (vs. normal liver
tissues) (Dunnett’s test).
2.6. Involvement of MAFB, MAFF, and TFPI2 in the Progression and Prognosis of HCC
We further analyzed gene expression in patients with HCC by using the data generated by the
TCGA Research [21]. HCC patients with vascular invasion showed significantly low MAFB expression
while other genes remained unaffected (see Figure 7A). In addition, the expression of TFPI2 and RARβ
was significantly low in patients with metastasis (see Figure 7B). This suggests that these genes may
impact the prognosis of HCC patients.
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Figure 7. Correlation of gene expression in the livers of patients with HCC with vascular invasion and
metastasis from the TCGA cohort. (A) Box and whisker plots of log 2 gene expression levels in HCC
livers with (red) or without (blue) vascular invasion (TFPI2, n = 108 vs. 204, RARα, RARβ, MAFB,
MAFF, n = 109 vs. 207). (B) Box and whisker plots of log 2 gene expression levels in HCC livers with
(red) or without (blue) metastasis (n = 4 vs. 267). Boxes indicate first and third quartiles and median
values and whiskers represent 5 and 95 percentiles. Open circulars indicate outliers. p values shown
were calculated by the Welch’s t-test.
Kaplan–Meier analysis revealed that the expression of TFPI2, RARα, RARβ, MAFB, and MAFF
does not influence the disease-free survival (DFS) period (see Figure S8 [22]). However, patients with
high MAFB expression in TFPI2 high or MAFF high groups showed longer DFS period than those with
low MAFB expression (see Figures 8A,B and S8B). In contrast, patients with high MAFF expression
in TFPI2 low or MAFB low groups showed poorer DFS than those with low MAFF expression
(see Figures 8C,D and S8B). There was no significant difference among other groups including RARα
and RARβ (see Figure S8B [22]).
Int. J. Mol. Sci. 2018, 19, x 8 of 16 
 
Figure 7. Cor elation of gene xpre sion in the livers of patients with HCC with vascular invasion 
and metastasis from the TCGA cohort. (A) Box and whisker plots of log 2 gene expression levels in 
HCC livers with (red) or without (blue) vascular invasion (TFPI2, n = 108 vs. 204, RARα, RARβ, 
MAFB, MAFF, n = 109 vs. 207). (B) Box and whisker plots of log 2 gene expression levels in HCC livers 
with (red) or without (blue) metastasis (n = 4 vs. 267). Boxes indicate first and third quartiles and 
median values and whiskers represent 5 and 95 percentiles. Open circulars indicate outliers. p values 
shown were calculated by the Welch’s t-test. 
Kaplan–Meier analysis revealed that the expression of TFPI2, RARα, RARβ, MAFB, and MAFF 
does not influence the disease-free survival (DFS) period (see Figure S8, [22]). However, patients with 
high MAFB expression in TFPI2 high or MAFF high groups showed longer DFS period than those 
with low MAFB expression (see Figures 8A,B and S8B). In contrast, patients with high MAFF 
expression in TFPI2 low or MAFB low groups showed poorer DFS than those with low MAFF 
expression (see Figures 8C,D and S8B). There was no significant differenc  am ng other groups 
including RARα and RARβ (see Figure S8B, [22]). 
 
Figure 8. Kaplan–Meier analyses of disease-free survival of HCC patients from the TCGA cohort. 
(A,B) Disease-free survival curves of patients with lower (blue) or higher (red) MAFB expression in 
HCC with higher TFPI2 (n = 68 or n = 93, respectively) (A) or higher MAFF (n = 83 or 70, respectively) 
(B) groups, (C,D) Disease-free survival curves of patients with lower (blue) or higher (red) MAFF 
expression in HCC with lower TFPI2 (n = 94 or n = 62, respectively) (C) or lower MAFB (n = 73 or n = 
83, respectively) (D) groups. P values shown were calculated by log-rank test. Median values of gene 
expression were used to divide the patients into the higher or lower groups. 
2.7. Biological Significance of MAFB-Regulated ATRA Target Genes 
The above findings in human HCC suggest anti-oncogenic properties of MAFB against MAFF. 
This prompted us to perform a microarray analysis by using the MAFB-knockdown and MAFF-
knockdown HuH7 cells (MBKD and MFKD cells, Figure S6A). The genes showing expression that 
was 1.5-fold or higher due to ATRA in all cell lines were analyzed and clustered into six groups (see 
Figure S9). Clusters A and D contained genes whose induction ratio was increased and decreased by 
shMAFF, which implies that retinoid-target genes are regulated by MAFF (see Figure S9A). Clusters 
B and E, respectively, comprised retinoid-target genes that were positively and negatively regulated 
Figure 8. Kaplan–Meier analyses of disease-free s rvival of H C patients from the TCGA cohort.
(A,B) Disease-free survival curves of patients with lower (blue) or higher (red) MAFB expression in
HCC with higher TFPI2 (n = 68 or n = 93, respectively) (A) or higher MAFF (n = 83 or 70, respectively)
(B) groups, (C,D) Disease-free survival curves of patients with lower (blue) or higher (red) MAFF
expression in HCC with lower TFPI2 (n = 94 or n = 62, respectively) (C) or lower MAFB (n = 73 or
n = 83, respectively) (D) groups. P values shown were calculated by log-rank test. Median values of
gene expression were used to divide the patients into the higher or lower groups.
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2.7. Biological Significance of MAFB-Regulated ATRA Target Genes
The above findings in human HCC suggest anti-oncogenic properties of MAFB against
MAFF. This prompted us to perform a microarray analysis by using the MAFB-knockdown and
MAFF-knockdown HuH7 cells (MBKD and MFKD cells, Figure S6A). The genes showing expression
that was 1.5-fold or higher due to ATRA in all cell lines were analyzed and clustered into six groups
(see Figure S9). Clusters A and D contained genes whose induction ratio was increased and decreased
by shMAFF, which implies that retinoid-target genes are regulated by MAFF (see Figure S9A). Clusters
B and E, respectively, comprised retinoid-target genes that were positively and negatively regulated by
MAFB (see Figure S9A). The genes in clusters C and F were, respectively, thought to be positively and
negatively regulated by MAFB and MAFF. There was no cluster indicating genes regulated by MAFB
and MAFF in an inverse manner (see Figure S9A).
The KEGG pathway analysis showed that the enriched pathways common to MAFB and
MAFF were retinol metabolism (hsa0083) and the adipocytokine signaling pathway (hsa04920)
(see Figure S9B). In addition, MAFB was thought to be involved in coagulation (hsa04610) and
MAFF in the inflammatory response (hsa04668, hsa04064, and hsa04670) (see Figure S9B).
3. Discussion
MAF transcription factor family members play a vital role in various biological processes. They are
divided into two groups based on structural characteristics including large MAFs, which involve
c-MAF, MAFA, and MAFB, and small MAFs, which include MAFF, MAFG, and MAFK (see review [23]).
Since small MAFs lack the transactivation domain, they can positively and negatively regulate
transcription depending on their dimerization partners [24].
In the liver, small MAFs generally form a heterodimer with the Cap’n’Collar proteins to
regulate cytoprotective genes related to xenobiotic metabolism, the oxidative stress response,
and the redox homeostasis [24]. MAFG was recently revealed as a transcriptional repressor of
bile acid synthesis and metabolism [25]. Although mice that lack only one of the small MAFs are
viable and show mild phenotypic changes, knockout of all three small MAFs result in embryonic
lethality with severe hypoplasia in the fetal liver due to increased apoptosis of hepatocytes and
erythrocytes [26]. This suggests that despite being functionally redundant, small MAFs are crucial in
proper liver development.
MAFB plays a role in the development of erythrocytes, pancreatic β cells, renal podocytes,
and macrophages in the fetal liver [27–29]. The anti-oncogenic potential of MAFB is not entirely clear
and tends to depend on the cellular context. Additionally, downregulation of MAFB expression is
observed in neoplastic liver lesions induced by the activation of γ-aminobutyric acid A receptor in
an N-diethylnitrosamine-induced hepatocarcinogenesis model [30]. By contrast, MAFB overexpression
in hematopoietic stem/progenitor cells leads to the development of leukemia and myeloma [31].
Although MAFB transforms primary fibroblasts with an efficiency lower than that of c-MAF and
MAFA [32], large MAFs do not transform chicken embryonic neuroretina cells but rather induce
differentiation of crystallin-producing cells and counteract the proliferation of mutant RAS-transformed
neuroretina cells [33]. In addition, MAFB induces the differentiation into macrophages of transformed
hematopoietic precursor cells. c-MAF is thought to act as a tumor suppressor gene in prostate
cancer [34,35].
We therefore hypothesized that MAFB confers its anti-oncogenic effects by antagonizing MAFF
since MAFB-induced activation of the TFPI2 promoter remained unaffected by MAFF (see Figure S4B).
Furthermore, the expression of MAFB in HCC tissues was significantly downregulated as the tumor
stage increased (see Table S2). By contrast, the apparent difference in MAFB and MAFF expression
was not observed in the presence or absence of vascular invasion or metastasis and there were no
differences in DFS time based on individual gene expression. This might be attributable to the
functional redundancy of large as well as small MAFs. However, HCC patients with lower MAFB
and higher MAFF expression (median DFS time: 11.5 months) showed poorer DFS than those with
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higher expression of both MAFB and MAFF (35.8 months, p = 0.003) and those with lower expression
of both MAFB and MAFF (25.3 months, p = 0.017) (see Figures 8B,D and S8B). This suggests that MAFF
functions as an oncogene in the absence of MAFB. Therefore, the complex interaction of MAFs must be
considered when attempting to understand the physiological functions of MAFs in patients with HCC.
To our knowledge, this is the first report demonstrating the regulatory function of MAFB and
MAFF in HCC cell invasion. TFPI2 is well known as a tumor suppressor gene and inhibits not only
the factor VIIa/tissue factor complex but also plasmin, kallikrein, and trypsin [12]. By virtue of this
property, TFPI2 also inhibits the activation of MMP1 and 3 by plasmin and trypsin [16]. However,
Neaud et al. reported that TFPI2 showed a pro-invasive effect on HCC cell lines, which includes
HepG2 and HuH7 cells [36]. They also demonstrated that the neutralization of factor VII with its
specific antibody abolished the TFPI2-induced invasion of HCC cell lines [36]. The reason for this
discrepancy is not clear at present. Our pathway analysis suggested that knockdown of TFPI2 in HuH7
cells influences the coagulation pathway (see cluster D in Figure S2). In addition, retinoid-target genes
regulated by MAFB were also suggested to be classified into the coagulation pathway (clusters B & E
in Figure S9). The modulation of clotting factor expression by ATRA may underlie the discrepancy
effects of TFPI2 on cancer cell invasion.
Furthermore, the expression of TFPI2 is frequently silenced by promoter methylation in many
tumor tissues including HCC [15,16,37,38]. Therefore, the restoration of TFPI2 expression suppresses
the invasiveness of malignant tumors [16]. In contrast to the silencing mechanism, the transcription
factors that are involved in TFPI2 transcription have not been well studied. In the present study,
we identified the members belonging to the MAF transcription factor family as novel regulators
of RARα transactivation activity in TFPI2 expression. We did not observe ATRA-induced TFPI2
expression in HepG2 cells (see Figure 1A). This may be explained by relatively low expression of
MAFB in HepG2 cells when compared with HuH7 cells (see Figure S10A). The reporter assay in HepG2
cells demonstrated that RARα as well as MAFB and MAFF did not markedly affected TFPI2 promoter
activity even in the presence of ATRA (see Figure S10B). However, when co-transfected MAFB or
MAFF with RARα, MAFB significantly activated the promoter while MAFF suppressed it, which was
observed in HuH7 cells (see Figure S10B). Therefore, it is implied that MAFB expression in HepG2
cells may not be sufficient for RARα to induce TFPI2 expression.
By dividing the HCC patients into groups with higher or lower TFPI2 expression, it was seen
that in the higher TFPI2 group, those with higher MAFB expression showed better DFS than those
with lower MAFB expression (29.3 months vs. 12.9 months, p = 0.040) while, in the lower TFPI2 group,
those with lower MAFF showed better DFS than those with higher MAFF expression (25.3 months
vs. 16.5 months, p = 0.033) (see Figure 7A,C and Figure S8B). These results suggest that MAFB and
MAFF determine TFPI2 expression along with the epigenetic mechanisms. The limitations of our study
include the inability to ascertain the correlation between RARα expression and HCC malignancy in
combination with the expression of other genes. Low body retinoid stores are frequently observed
in patients with chronic liver diseases including those with HCC [39,40]. It has also been shown
that retinoid supplementation significantly improves the prognosis of patients with the hepatitis C
virus-related HCC [41]. Therefore, it is likely that the activation of RARα by administration of retinoids
possibly provides this benefit through TFPI2.
To summarize, TFPI2 is an anti-oncogene suppressing HCC invasion whose expression is
regulated epigenetically and by retinoids. Moreover, MAFB and MAFF are novel regulators of RARα
at least with respect to the transcription of TFPI2 (see Figure S11). This system may be implicated in
the pathogenesis and progression of HCC and can be promising as a target for preventing and treating
HCC in addition to predicting HCC prognosis.
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4. Materials and Methods
4.1. Materials
The HuH7, HepG2, and KMST-6 cells, in addition to the plasmid DNAs (pDNAs) expressing
human RXRα and MAFG, were purchased from the RIKEN BRC (Tsukuba, Japan) through the
National Bio-Resource Project of the MEXT, Japan. The PDNA-expressing mouse Maf and those
expressing mouse MafA or MafB were kindly provided by Hiroshi Nakajima (Graduate School of
Medicine, Chiba University, Chiba, Japan) [42] and Satoru Takahashi (Faculty of Medicine, University
of Tsukuba, Tsukuba, Japan) [43,44]. PDNAs expressing MAFF, MAFK, and RARα were obtained
from NITE Biological Resource Center (Kisarazu, Japan). ShRNA expression vectors targeting TFPI2
(shTFPI2-1, TRCN0000072723; shTFPI2-2, TRCN0000072726), RARα (shRARα, TRCN0000020373),
MAFB (shMAFB, TRCN0000017680), and MAFF (shMAFF, TRCN0000016448) along with pLKO.1-puro
Non-Target shRNA (shNT) and fetal bovine serum (FBS), which were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Dual luciferase assay reagents and luciferase-expressing pDNAs were acquired
from Promega (Madison, WI, USA). The cell invasion assay kit (medium basement membrane
extract), QuikChange Lightning Site-Directed Mutagenesis Kit, and Viofectin transfection reagent
were respectively purchased from Trevigen, Inc. (Gaithersburg, MD, USA), Agilent Technologies
(Santa Clara, CA, USA), and Viogene (New Taipei City, Taiwan). ReverTra Ace, Thunderbird
SYBR qPCR Mix, and KOD-Plus-Neo were purchased from Toyobo Co., Ltd. (Osaka, Japan).
The Anti-Flag antibody and its magnetic agarose beads were purchased from MBL (Nagoya, Japan) and
anti-Strep-tag II (ab76949) and anti-TFPI2 (ab186747) antibodies from Abcam (Cambridge, UK). ATRA
and anti-GAPDH antibody (sc-365062) was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Dulbecco’s modified Eagle’s medium (DMEM), ActD, ethanol (EtOH), puromycin, G418,
and Sepasol-RNA I super G were purchased from Nacalai Tesque Inc. (Kyoto, Japan). AzC and SAHA
were bought from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan).
4.2. Cell Culture and ATRA Treatments
HuH7 and HepG2 cells were cultured in DMEM supplemented with 10% FBS at 37 ◦C with 5%
CO2. Four milliliters of ATRA stock solution was prepared with EtOH. When treating the cells with
ATRA, the same volume of EtOH was added to control cells at a concentration of <0.1%.
4.3. Treatment with ActD, AzC, and SAHA
To suppress transcription, HuH7 and HepG2 cells were pre-treated with 5 µg/mL ActD for 30 min
after which they were separately incubated with EtOH and 2 µM ATRA for 0 to 12 h. To check whether
epigenetic mechanisms were involved, HuH7 and HepG2 cells were pre-treated with 2 µM SAHA for
36 h or with 2 µM AzC for 108 h after which the cells were separately incubated with EtOH and 2 µM
ATRA for 12 h in the presence of SAHA or AzC.
4.4. Establishment of Transgenic Cell Lines
HuH7 cells were transfected with pDNAs of shNT, shTFPI2, shRARα, shMAFB, and shMAFF by
Viofectin, which was followed by puromycin selection. HuH7 cells transfected with empty pDNA,
pDNA expressing mouse MAFB, or human MAFF were selected by G418. Gene expression in isolated
clones was analyzed by using reverse-transcription quantitative PCR.
4.5. Determination of mRNA Levels
The cells were lysed with sepazol and total RNA was purified according to the manufacturer’s
instructions. Complementary DNA (cDNA) was synthesized with ReverTra Ace and was analyzed by
quantitative PCR with Thunderbird SYBR qPCR Mix. The following PCR primers were used: β-actin,
GATGCAGAAGGAGATCACTGC (sense) and TGATCCACATCTGCTGGAAG (anti-sense); TFPI2,
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GAACCTGTGATGCTTTCACC (sense) and TCCGGATTCTACTGGCAAAG (anti-sense); MAFB,
TGAACTTTGCGCGTTAAGCC (sense) and TCCTTTCCTCGTTGCTCTCTTC (anti-sense); mouse
MAFB, AGTCGTGCAGGTATAAACGC (sense) and GAGTTTCTCGCACTTGACCTTG (anti-sense);
MAFF, ATCCCCTATCCAGCAAAGCTC (sense) and TTGAGCCGTGTCACCTCCTC (anti-sense);
RARα, CATTGAGAAGGTGCGCAAAG (sense) and AGACACGTTGTTCTGAGCTG (anti-sense);
RARB, GAAAAAGACGACCCAGCAAG (sense) and ATGAGAGGTGGCATTGATCC (anti-sense).
Relative mRNA levels were measured using the 2−∆∆Ct method with β-actin as an internal control.
4.6. Cell Invasion Assay
Cells pre-cultured in serum-free DMEM for 24 h were seeded in top chambers containing
a medium amount of basement membrane extract and were incubated in serum-free DMEM
supplemented with 0–4 µM of ATRA for 48 h while the bottom chambers were filled with DMEM
containing 10% FBS as well as the same concentration of ATRA. After the incubation, the cells remaining
in the top chambers were discarded and invasive cells were recovered using a dissociation solution
provided through the cell invasion assay kit. The recovered cells were stained with calcein AM and
calcein fluorescence was measured at an excitation of 485 nm and an emission of 520 nm.
4.7. Dual Reporter Assay
To construct a human TFPI2 promoter reporter vector, PCR cloning was performed with LA Taq
with GC buffer I (TaKaRa Bio, Otsu, Japan). In the reaction, genomic DNA isolated from a human
immortalized the fibroblast cell line, KMST-6, was used as a template and the following oligoDNAs
were used as primers: hTFPI2pro-For, CGTCCTCGAGGTCCACACAAAGCAGCTT; hTFPI2pro-Rev,
GTCGAGATCTGGGCAAGGCGTCCGAGAAA. The PCR products were digested with XhoI and
BglII, which was followed by ligation into the same restriction sites of pGL4.10 [luc2]. The promoter
sequence was confirmed by DNA sequencing. Site-directed mutagenesis was performed according to











These reporter vectors and pDNAs expressing transcription factors were transfected into
HuH7 cells using Viofectin. The dual luciferase assay was performed 48 h after transfection using
pGL4.74[hRluc/TK] expressing renilla luciferase with the herpes simplex virus thymidine kinase
promoter (Promega) acting as a transfection control.
4.8. Gene Expression Data in Clinical Samples
CDNAs derived from various liver tissues (TissueScan Liver Cancer Tissue qPCR Panel I) were
purchased from Origene Technologies (Rockville, MD, USA). RNA-seq data of HCC tissues were
obtained from the TCGA Research Network [21], which also provides DFS times, and the presence of
vascular invasion or metastasis.
4.9. Transcription Profiling
MRNAs were recovered from cells treated with EtOH or 2 µM ATRA for 12 h by using sepazol
and were purified with the RNeasy Plus Mini Kit (QIAGEN, Redwood City, CA, USA). The expression
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profile was analyzed by the Human HT-12 v4 Expression BeadChip (Illumina, San Diego, CA, USA) at
Macrogen Japan (Kyoto, Japan). The microarray data were deposited in the ArrayExpress database
(Accession No. E-MTAB-6447). Cluster analysis was performed using Cluster 3.0 and the results were
visualized using Java Tree View. The Database for Annotation, Visualization, and Integrated Discovery
online tool was used to enrich the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway.
4.10. Immunoprecipitation-Western Blotting
PDNA expressing Strep-tag-fused RARα was constructed as follows. Internal ribosome entry
site of pIRES2 DsRed-Express2 (Clontech, Foster City, CA, USA) was amplified by KOD-Plus-Neo
with the forward primer, GCGGGTCGACGCCCCTCTCCCTCCCC, and the reverse primer, GCGGGG
ATCCTGTGGCCATATTATCATCGT. The PCR product was digested with SalI and BamHI and was
then ligated into the same restriction sites of pAcGFP-N1 (Clontech), which produced pIRES2-AcGFP.
RARα cDNA was amplified by using pDNA expressing human RARα as a template with the forward
primer, GGCGCTCGAGCACTGTTGGCCTACTGG, and the reverse primer, CGCCGAATTCTT
ACTTTTCAAACTGCGGATGGCTCCACGGGGAGTGGGTGGCCG, which fuses a Strep tag to the
C-terminal of RARα. The PCR product was digested with XhoI and EcoRI and was then ligated into
the same restriction sites of pIRES2-AcGFP. This resulted in a pDNA expressing Strep-tag-fused RARα.
PDNAs expressing Flag-tag-fused MafB and MAFF were constructed as follows. Mouse
MafB and human MAFF cDNAs were amplified by KOD-Plus-Neo with the MafB forward primer,
GGCGGCTAGCCACCATGGACTACAAGGATGACGATGACAAGATGGCCGCGGAGCTGAGC,
which fuses a Flag tag to the N-terminal of MafB and the MafB reverse primer, CGCCGTCGACTC
ACAGAAAGAACTCAGGAGAG, in addition to the MAFF forward primer, GGCGGCTAGCCAC
CATGGACTACAAGGATGACGATGACAAGATGTCTGTGGATCCCCTATC, which fuses a Flag tag to
the N-terminal of MAFF and the MAFF reverse primer, GGGGGTCGACTAGGAGCAGGAGGCCGGG.
The PCR products were digested with NheI and SalI and were then ligated into the same restriction
sites of pIRES2 DsRed-Express2, which result in pDNAs expressing Flag-tag-fused MAFB and MAFF.
The pDNA expressing Strep-tag-fused RARα was co-transfected into HEK293 cells with either
empty pDNA or pDNAs expressing Flag-tag-fused MAFB or MAFF. Forty-two hours after transfection,
EtOH and 2 µM ATRA were separately added to the cell mixture. Following a six hour incubation,
the cells were lysed with NP40 buffer (1% NP40, 50 mM Tris-HCl [pH 8.0] and 150 mM NaCl).
The lysates were incubated overnight with anti-Flag-tag antibody-conjugated magnetic beads at 4 ◦C.
The whole-cell lysates and precipitates were separated by using SDS-PAGE and immunoblotting with
anti-Strep-tag and anti-Flag-tag antibodies.
4.11. Statistical Analysis
Data were expressed as mean ± standard deviation. Statistical analysis was performed using
SPSS (version 24, SPSS Inc., Chicago, IL, USA). Probability values less than 0.05 were considered
statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/5/
1450/s1.
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